You are being asked to take part in this study because you have inflammatory breast cancer
(IBC) or triple negative breast cancer (TNBC) that is metastatic (has spread to other parts
of the body).
The goal of this clinical research study is to learn if pembrolizumab (also called MK-3475
and Keytruda) can help to control metastatic IBC and TNBC. The safety of this drug will also
This is an investigational study. Pembrolizumab is FDA approved and commercially available
for the treatment of metastatic melanoma. Its use in patients with metastatic IBC and TNBC is
investigational. The study doctor can describe how the study drug is designed to work.
Up to 35 participants will be enrolled in this study. All will take part in at MD Anderson.